Integra LifeSciences Holdings Corporation — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual Form 10-K, not a standalone fourth-quarter report, although fourth-quarter seasonality is discussed.
Business Context
Integra develops and sells medical technologies in more than 130 countries through two reportable segments: Codman Specialty Surgical, focused primarily on neurosurgery, neurocritical care and surgical instruments; and Tissue Technologies, focused on wound reconstruction, surgical reconstruction, peripheral nerve repair and related regenerative products. CSS represented approximately two-thirds of revenue and TT approximately one-third.
- CSS revenue was $1,019.6 million; TT revenue was $538.1 million.
- On December 6, 2022, Integra acquired Surgical Innovation Associates for $51.5 million, adding the DuraSorb resorbable synthetic matrix platform.
- In August 2022, Integra sold its non-core traditional wound care business for $28.8 million, including $27.8 million in cash and up to $1.0 million of contingent consideration.
Financial Performance and Liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $1,557.7 million | $1,542.4 million | Up 1.0% |
| Gross profit | $970.3 million | $944.6 million | Up $25.7 million |
| Gross margin | 62.3% | 61.2% | Up 110 basis points |
| Operating income | $238.9 million | $197.2 million | Up 21.1% |
| Net income | $180.6 million | $169.1 million | Up 6.8% |
| Diluted earnings per share | $2.16 | $1.98 | Up 9.1% |
| Operating cash flow | $264.5 million | $312.4 million | Down $48.0 million |
- Net margin was approximately 11.6% in 2022, compared with approximately 11.0% in 2021; operating margin was approximately 15.3%, compared with 12.8%.
- Revenue growth included a $37.9 million unfavorable foreign-exchange impact and a $10.2 million reduction related to the traditional wound care divestiture. Excluding those effects, domestic revenue increased 3.8% and international revenue increased 4.8%.
- CSS revenue declined 0.6% as reported but increased $28.4 million excluding foreign exchange. TT revenue increased 4.0% as reported and increased $34.9 million excluding foreign exchange and the divestiture effect.
- Cash and cash equivalents were $456.7 million at December 31, 2022, versus $513.4 million at December 31, 2021. Working capital increased to $840.6 million from $813.7 million.
- Capital expenditures were $42.3 million. Investing cash outflows included the $51.5 million SIA acquisition, partly offset by $24.0 million of net proceeds from the traditional wound care sale.
- External debt was approximately $1.5 billion. Balance-sheet borrowings included $771.3 million under the term loan, $104.7 million under the securitization facility and $575.0 million principal amount of convertible notes, plus current maturities.
- The Company was in compliance with its debt covenants at year-end and stated that cash and available borrowings should be sufficient to fund operations and capital expenditures for the next twelve months.
Material Changes Versus the Prior Comparable Period
- Revenue increased modestly despite currency headwinds, supply-chain constraints and the divestiture of traditional wound care.
- Gross margin improved primarily because of lower ACell inventory step-up amortization, partially offset by CereLink recall costs, unfavorable mix and higher material and labor costs.
- Operating expenses declined 2.1% to $731.4 million. Lower selling, general and administrative expense and amortization more than offset higher research and development spending.
- Net income benefited from higher operating income and a lower effective tax rate of 15.6%, compared with 21.2% in 2021.
- Operating cash flow declined because of increased inventory and accounts receivable, including safety-stock investments made in response to supply-chain challenges.
- Financing cash usage increased to $252.0 million, primarily due to $125.0 million of share repurchases, $148.6 million of debt repayments and $24.6 million of cash taxes paid in net equity settlements.
Guidance, Outlook, Risks and Unusual Items
- Management estimated a 2023 worldwide effective tax rate of approximately 20.7%. No clear 2023 revenue or earnings guidance is provided in the filing text.
- Management expects approximately $82.3 million of annual amortization expense in 2023, with additional scheduled amortization thereafter.
- Integra initiated a voluntary global removal of all CereLink intracranial pressure monitors on August 18, 2022 after reports of out-of-range pressure readings. The Company recorded a $1.9 million provision for returns and a $0.8 million rework accrual.
- The TEI Boston facility remains subject to FDA remediation related to a 2019 Warning Letter and a 2021 Form 483. Products manufactured there represented approximately 5.3% of 2022 consolidated revenue. The filing states that the matters did not restrict manufacturing or shipments as of the filing date, but further regulatory action remains possible.
- EU Medical Device Regulation compliance expenditures were $45.1 million in 2022, with additional expenditures expected.
- SIA carries contingent consideration of up to $90.0 million: up to $50.0 million tied to revenue milestones and up to $40.0 million tied to FDA approval of DuraSorb for specified uses.
- Key risks include medical-device regulation and recalls, reimbursement and pricing pressure, supply-chain disruptions and inflation, foreign-exchange exposure, acquisition integration, cybersecurity, product liability, intellectual-property disputes and approximately $1.5 billion of debt.
- The Company has not paid cash dividends since formation. On January 26, 2023, it entered into a $150.0 million accelerated share repurchase agreement and initially received 2.1 million shares.
Important Facts for Investors to Verify
- Review the full debt maturity, interest-rate and covenant profile, particularly the 2025 term-loan and convertible-note maturities and the transition from LIBOR to SOFR.
- Assess the financial impact, timing and regulatory status of the CereLink removal and potential return to market.
- Monitor FDA remediation at the TEI Boston facility and the effect on SIA and SurgiMend PMA applications.
- Evaluate whether TT growth, including ACell and SIA products, offsets slower CSS performance and continued foreign-exchange pressure.
- Reconcile reported results with the $49.4 million of special charges in 2022, including acquisition, divestiture, integration, structural optimization and EU MDR costs.
- Review contingent consideration obligations and the assumptions supporting the $75.0 million developed-technology asset recorded in the SIA acquisition.
- Verify inventory growth, receivables trends and operating cash-flow conversion as supply-chain conditions normalize.